Clinical Trial Update: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating golimumab in Japanese patients with moderately to severely active ulcerative colitis has completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED | Results posted: 2017-02-17